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BACKGROUND: Recently, several genome-wide association studies (GWAS) have independently found numerous loci at which
common single-nucleotide polymorphisms (SNPs) modestly influence the risk of developing colorectal cancer. The aim of this study
was to test 11 loci, reported to be associated with an increased or decreased risk of colorectal cancer: 8q23.3 (rs16892766), 8q24.21
(rs6983267), 9p24 (rs719725), 10p14 (rs10795668), 11q23.1 (rs3802842), 14q22.2 (rs4444235), 15q13.3 (rs4779584), 16q22.1
(rs9929218), 18q21.1 (rs4939827), 19q13.1 (rs10411210) and 20p12.3 (rs961253), in a Swedish-based cohort.
METHODS: The cohort was composed of 1786 cases and 1749 controls that were genotyped and analysed statistically. Genotype–
phenotype analysis, for all 11 SNPs and sex, age of onset, family history of CRC and tumour location, was performed.
RESULTS: Of eleven loci, 5 showed statistically significant odds ratios similar to previously published findings: 8q23.3, 8q24.21, 10p14,
15q13.3 and 18q21.1. The remaining loci 11q23.1, 16q22.1, 19q13.1 and 20p12.3 showed weak trends but somehow similar to what
was previously published. The loci 9p24 and 14q22.2 could not be confirmed. We show a higher number of risk alleles in affected
individuals compared to controls. Four statistically significant genotype–phenotype associations were found; the G allele of
rs6983267 was associated to older age, the G allele of rs1075668 was associated with a younger age and sporadic cases, and the
T allele of rs10411210 was associated with younger age.
CONCLUSIONS: Our study, using a Swedish population, supports most genetic variants published in GWAS. More studies are needed
to validate the genotype–phenotype correlations.
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Until some years ago, the candidate-gene approach was the only
method available to the researchers for identifying potentially
pathogenic variants. However, the fast technological development
and the consequent acquisition of large amount of data in the past
decade shifted the focus of research to genome-wide association
studies (GWAS). Recent GWAS have identified multiple genetic
loci associated with an increased or decreased risk of colorectal
cancer (CRC) on 8q23.3, 8q24.21, 9p24, 10p14, 11q23.1, 14q22.2,
15q13.3, 16q22.1, 18q21.1, 19q13.1 and 20p12.3, explaining, at least
to some extent, the genetics behind CRC as a complex disease
(Broderick et al, 2007; Haiman et al, 2007; Tomlinson et al, 2007,
2008; Zanke et al, 2007; Houlston et al, 2008; Jaeger et al, 2008;
Tenesa et al, 2008). Each of these loci is associated with a modest
risk and, although fairly common they contribute very little to
the overall burden of CRC. This case–control study focused on
the known CRC single-nucleotide polymorphisms (SNPs) in a
Swedish-based cohort and to compare our results with previous
association studies in other populations. It also tested if there were
more CRC patients than controls among individuals with higher
number of risk alleles as reported previously (Tomlinson et al,
2010). Genotype–phenotype associations were analysed for age of
onset, sex, family history of CRC and tumour location.
MATERIALS AND METHODS
Subjects
The case cohort was composed of 1786 consecutive CRC patients
of Swedish origin recruited through the Swedish Low-Risk CRC
Study Group from 14 different hospitals from central Sweden
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sduring 2004–2006. The mean age (at diagnosis) was 68.6 years
(range 28–95 years), 53% were men and 47% were women and
22% had a family history of CRC among first- or second-degree
relatives. The control cohort was composed of 1749 individuals as
follows: 1319 blood donors from the general population between
the age of 18 and 65 years and 430 unaffected spouses of CRC
patients with the mean age of 66.3 (25–92) years, which were
cancer-free and did not have a family history of any type of cancer.
Loci and SNPs
Exploiting linkage disequilibrium between SNPs, we selected one
SNP from each locus among those published. Thus we genotyped
rs16892766 on 8q23.3, rs6983267 on 8q24.21, rs719725 on 9p24,
rs10795668 on 10p14, rs3802842 on 11q23.1, rs4444235 on 14q22.2,
rs4779584 on 15q13.3, rs9929218 on 16q22.1, rs4939827 on
18q21.1, rs10411210 on 19q13.1, rs961253 on 20p12.3 and excluded
the following from the analysis: rs355527 on 20p12.3 (tagged by
rs961253) and rs7259371 on 19q13.1 (tagged by rs10411210).
Genotyping
Genomic DNA was extracted from peripheral blood by standard
procedures. Six of the SNPs (rs9929218, rs719725, rs4444235,
rs4779584, rs10411210 and rs961253) were genotyped using TaqMan
SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA).
Genotyping and first-quality check of the remaining five SNPs
(rs6983267, rs16892766, rs10795668, rs4939827 and rs3802842) were
performed, using a technology developed by Nanogen, at deCode
Genetics, Reykjavik, Iceland (http://www.decode.com).
Quality control
Sequencing was performed using Big-Dye terminator v3.1 cycle
sequencing kit (Applied Biosystems), and fragments were sepa-
rated on an ABI 3730 XL capillary sequencer. Chromatograms were
analysed using SeqScape v2.5 (Applied Biosystems). Primers and
amplification conditions are available upon request.
Genotype–phenotype analysis
We studied sex, age of onset (early vs late, 460 years), family
history of CRC (any case of CRC among first- or second-degree
relatives), location, colon vs rectum and right vs left (proximal and
distal to the splenic flexure).
Statistical analysis
Deviations of the genotype frequencies in cases and controls from
those expected under Hardy–Weinberg equilibrium were calcu-
lated by w
2-tests (one degree of freedom). Allelic frequencies of the
SNPs in the case and control groups were compared using a w
2-test
(allele 1 (common) vs allele 2 (minor)), except for rs6983267 where
the common allele is suggested to be the risk allele (Tomlinson
et al, 2007). To make comparisons, we chose to present risk and
common allele according to previous publications. Analyses were
also performed under various types of genetic models including
the comparison of homozygotes (genotype 11 vs 22), the dominant
(11 vs (12þ22)), the recessive ((11þ12) vs 22) models and the
allele frequency difference ((1) vs (2)). In addition, Armitage’s
trend test, which takes into account the individuals’ genotypes
rather than just alleles, (Sasieni, 1997) was performed using
the DeFinetti programme provided as an online source
(http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). The signi-
ficance level for statistical tests was set at 0.05. Odds ratios (ORs),
their 95% confidence intervals (CIs) and their corresponding
P-values were calculated using the same programme. The analyses
were validated using Statistica 7.0 (StatSoft Inc., Tulsa, OK, USA).
Statistical analysis for the clinical parameters was carried out with
Statistica, using cross-tabulation analysis. Pearson w
2-test was used
to calculate the P-value, and the level of significance was set at 0.05.
RESULTS
Genotype frequencies of cases and controls as well as ORs and
P-values for the different analyses are shown in Table 1. Significant
associations between 5 of the 11 genotyped SNPs (rs16892766,
rs6983267, rs10795668, rs4779584 and rs4939827) and CRC risk
were confirmed and showed similar ORs as in previous publica-
tions (Broderick et al, 2007; Tomlinson et al, 2007, 2008; Jaeger
et al, 2008). For SNP rs16892766 on 8q23.3, an increased risk of
CRC was identified (Po0.002 for all analyses except the recessive
model) with the highest OR equal to 1.34 (1.13–1.60) for the
heterozygous. Likewise, the increased risk suggested for the variant
rs6983267 on 8q24.21 was confirmed in all the analyses, with the
highest OR equal to 1.37 (1.13–1.67) for the homozygous state.
rs4779584 on 15q13.3 has been associated with an increased risk
that could be confirmed for the heterozygous individuals, OR¼1.18
(1.02–1.36). The protected effects suggested for rs10795668 on
10p14 and rs4939827 on 18q21.1 were both confirmed for homo-
zygous and heterozygous with an OR equal to 0.66 (0.52–0.83) and
OR 0.82 (0.70–0.96), respectively. The ORs for rs3802842 on 11q23.1
showed a trend with an OR equal to 1.27 (NS) for homozygous. The
rs9929218 on 16q22.1, rs10411210 on 19q13.1 and rs961253 on
20p12.3 showed weak trends in the same direction as published
(NS), whereas the two SNPs rs719725 on 9p24 and rs4444235 on
14q22.2 were not confirmed. The distribution of risk alleles between
cases and controls in the Swedish population is shown in Figure 1.
There is a clear shift with a higher number of alleles in affected
individuals compared to controls.
Genotype–phenotype analysis was performed for all 11 loci and
for sex, age, family history and tumour location, and the P-values
for all analyses are shown in Table 2. Four associations were found,
three for age and one for family history (Table 3). Being
homozygous for the risk allele G for rs6983267 showed association
to older age (P¼0.0014). In contrast, for rs1075668 the risk allele
G was associated with younger age (P¼0.035) and sporadic cases
(P¼0.047). The T allele of rs10411210 was associated with younger
age (P¼0.045) in homozygotes (Table 3).
DISCUSSION
We studied SNPs on 11 loci published to be associated with an
increased or decreased risk for CRC and were able to show
statistically significant results for 5 of them. The first SNP,
rs6983267 on 8q24.21, was published by Tomlinson et al (2007),
where the most common allele G was suggested to be the risk
allele. Our study showed similar results as previous studies in
other populations (Berndt et al, 2008; Tuupanen et al, 2008;
Wokolorczyk et al, 2008; Curtin et al, 2009; Middeldorp et al,
2009). Likewise, the SNP rs16892766 on 8q23.3 was similar to both
the GWAS study and one replicative study (Tomlinson et al, 2008;
Wijnen et al, 2009). The protective effect associated with
rs10795668 on 10p14 was confirmed for homozygous carriers in
the Swedish material (Tomlinson et al, 2008). The SNP rs4779584
on 15q13.3, published by Jaeger et al (2008) as a risk association
with CRC was confirmed by us. For the SNP rs4939827 on 18q21.1,
Broderick et al published the variant to be protective, which could
also be shown by us and one previous study (Curtin et al, 2009).
The SNP rs3802842 on 11q23.1 was first published by Tenesa and
co-workers and confirmed by others (Pittman et al, 2008;
Middeldorp et al, 2009; Wijnen et al, 2009). Our results were
similar, but not statistically significant. This discrepancy could be
due to different populations, sample size or study design. Wijnen
et al (2009) used a Dutch population, and used mismatch repair
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Locus/SNP OR published Genotypes No cases (%) No controls (%) OR (95% CI) P-values
8q23.3 AA 1379 (79) 1404(83) 1
rs16892766 1.27 (het) AC 356 (20) 270 (16) 1.34 (1.13–1.60) 0.0009
1.43 (hom) CC 20 (1) 17 (1) 1.20 (0.63–2.30) 0.586
Tomlinson et al, 2008 AC+CC 1.33 (1.13–1.58) 0.0009
Allelic 1.29 (1.10–1.51) 0.0016
Trend 1.26 0.0017
8q24.21 TT 397 (23) 332 (19) 1
rs6983267 1.27 (het) TG 890 (51) 892 (51) 1.20 (1.01–1.43) 0.04
1.47 (hom) GG 450 (26) 517 (30) 1.37 (1.13–1.67) 0.001
Tomlinson et al, 2007 AG+GG 1.26 (1.07–1.48) 0.006
Allelic 1.16 (1.06–1.28) 0.0015
Trend 1.17 0.001
9p24 1.14 (com) AA 672 (39) 669 (39) 1
rs719725 AC 821 (48) 797 (46) 1.03 (0.89–1.19) 0.733
Zanke et al, 2007 CC 231 (13) 253 (15) 0.91 (0.74–1.12) 0.368
AC+CC 0.997(0.87–1.14) 0.971
Allelic 0.97 (0.88–1.07) 0.554
Trend 0.96 0.554
10p14 GG 853 (48) 745 (44) 1
rs10795668 0.87 (het) GA 779 (44) 754 (44) 0.90 (0.78–1.04) 0.151
0.80 (hom) AA 148 (8) 197 (12) 0.66 (0.52–0.83) 0.0004
Tomlinson et al, 2008 GA+AA 0.85 (0.75–0.97) 0.018
Allelic 0.85 (0.76–0.94) 0.001
Trend 0.83 0.001
11q23.1 1.11 (com) AA 941 (53) 926 (55) 1
rs3802842 AC 688 (39) 656 (39) 1.03 (0.90–1.19) 0.659
Tenesa et al, 2008 CC 142 (8) 110 (6) 1.27 (0.98–1.66) 0.076
AC+CC 1.07 (0.93–1.22) 0.347
Allelic 1.08 (0.97–1.21) 0.143
Trend 1.1 0.145
14q22.2 TT 573 (33) 533 (32) 1
rs4444235 1.13 (het) TC 829 (47) 838 (49) 0.92 (0.79–1.07) 0.284
1.23 (hom) CC 356 (20) 326 (19) 1.02 (0.84–1.23) 0.872
Houlston et al, 2008 TC+CC 0.95 (0.82–1.09) 0.455
Allelic 0.997(0.91–1.10) 0.951
Trend 1.00 0.952
15q13.3 CC 1050 (61) 1104 (65) 1
rs4779584 1.23 (het) CT 572 (33) 511 (30) 1.18 (1.02–1.36) 0.029
1.70 (hom) TT 94 (6) 89 (5) 1.11 (0.82–1.50) 0.496
Jaeger et al, 2008 CT+TT 1.17 (1.02–1.34) 0.029
Allelic 1.12 (1.00–1.26) 0.051
Trend 1.096 0.057
16q22.1 GG 929 (53) 913 (54) 1
rs9929218 0.92 (het) GA 700 (40) 648 (38) 1.06 (0.92–1.22) 0.404
0.82 (hom) AA 113 (7) 138 (8) 0.81 (0.62–1.05) 0.108
Houlston et al, 2008 GA+AA 1.02 (0.90–1.16) 0.810
Allelic 1.12 (1.00–1.26) 0.051
Trend 0.945 0.566
18q21.1 TT 501 (28) 408 (24) 1
rs4939827 0.86 (het) TC 886 (50) 884 (53) 0.82 (0.70–0.96) 0.013
0.73 (hom) CC 395 (22) 387 (23) 0.83 (0.69–1.01) 0.059
Broderick et al, 2007 TC+CC 0.82 (0.71–0.96) 0.011
Allelic 0.91 (0.83–1.00) 0.051
Trend 0.91 0.048
19q13.1 CC 1490 (84) 1421(83) 1
rs10411210 0.87 (het) CT 264 (15) 272 (16) 0.93 (0.77–1.11) 0.411
0.72 (hom) TT 13 (1) 14 (1) 0.89 (0.42–1.89) 0.753
Houlston et al, 2008 CT+TT 0.92 (0.77–1.11) 0.389
Allelic 0.93 (0.78–1.10) 0.385
Trend 0.930 0.387
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samples (995 cases and 1340 controls) used by Middeldorp et al
(2009) were familial cases and Pittman et al (2008) used eight
independent case–control series (10638 cases and 10457 controls)
and were able to confirm significant values for most of the
populations.
No association was detected for rs719725 on 9p24, initially
reported in cohorts from Canada, the United States, Newfound-
land, Scotland and France, which the authors themselves were
unable to replicate in a second French cohort (Zanke et al, 2007).
Later it was confirmed in cohorts from the American, Canadian
and Australian populations (Poynter et al, 2007). Even though the
distribution of the three genotypes was the same, we hypothesise
that this negative result could be due to its population specificity
and the causal SNP being on different haplotypes or were these
results false positives. A study using British and American cohorts
was also unable to detect any association for this SNP (Curtin et al,
2009).
To our knowledge, none of the remaining four SNPs has been
studied in other populations yet. In fact, the confirmed five loci
were the first ones to be published whereas the SNPs on 14q22.2,
16q22.1, 19q13.1 and 20p12.3 were only captured by meta-analysis
of large GWAS (Houlston et al, 2008), suggesting that these four
could be more difficult to replicate in follow-up studies. The three
SNPs on 16q22.1, 19q13.1 and 20p12.3 did not show statistically
significant values in our study. However, when looking at the ORs
in the Swedish samples, association was suggested but with a wider
CI compared to the first report (Houlston et al, 2008). Finally, we
were unable to confirm association to CRC risk for rs4444235 on
14q22.2 (Houlston et al, 2008), which again could be due to a
smaller size or possibly a population difference.
Another possible explanation for the different results could
depend on different genotype frequencies among populations or
methods used for genotyping. For all SNPs the genotype
frequencies in Swedish samples were similar to published data.
Regarding methods, SNP arrays were used for the GWAS, whereas
other studies used Sequenom’s iPLEX Gold (San Diego, CA, USA),
genomic sequencing, SNPlex, PCR KASPar or TaqMan. This does
not immediately explain the different results in the Swedish
material. Because four of the five SNPs genotyped by DeCode and
rs4778495 genotyped in Edinburgh using TaqMan were confirmed,
while none of the five (rs9929218, rs719725, rs4444235, rs10411210
and rs961253) carried out in our lab showed statistically significant
results we validated the results from our TaqMan analysis. In total
1000 cases and 1000 controls were sequenced for the five SNPs.
The concordance was 99.8%, why we do not think that the method
explains the difference between our study results and previous
publications.
Carrying one risk variant alone is neither necessary nor sufficient
for developing CRC. However, in Figure 1 we show support for the
general idea that the CRC patients carry more risk alleles compared
to controls. For both cases and controls, the distribution is outlined
in the diagram of carriers with a shift toward higher numbers of
risk alleles in affected individuals, in line with what has been
published (Tomlinson et al, 2010). Even though we did not confirm
all SNPs, and used 11 SNPs instead of 10, the distribution of risk
alleles showed very similar data (Figure 1) to what was published
that further strengthens the results and confirms the genetic
contribution by the alleles overall (Tomlinson et al, 2010).
The genotype–phenotype analysis interestingly showed four
associations for three SNPs. Other studies have published
genotype–phenotype analysis for only one of the loci, 8q24.21,
and sex, tumour site, age at diagnosis and family history (Haiman
et al, 2007; Poynter et al, 2007; Tuupanen et al, 2008). We report an
association to age for rs6983267 on 8q24.21; the risk allele G was
associated to our older patients (P¼0.0014). This was not seen in
any of the other studies (Haiman et al, 2007; Poynter et al, 2007;
Tuupanen et al, 2008), perhaps because of the different age groups
used. In contrast to our study and the two other studies, Tuupanen
et al (2008) for the same SNP reported an association to family
history. This is not likely to depend on the definition of family
history, because only our study used a different classification from
the other three. In line with our results, no one found any support
for sex or tumour site (Haiman et al, 2007; Poynter et al, 2007;
Tuupanen et al, 2008). For rs10795668 on 10p14, we showed
association to age and family history. Being homozygous for the
risk alleles was associated to younger patients (P¼0.035) and to
sporadic cases (P¼0.047). For rs10411210 an association was
identified for being homozygous for the risk allele in younger
patients (P¼0.045). Replications of these genotype–phenotype
analyses are needed before any conclusion can be made.
The genetic contribution to CRC as a whole has been estimated
to be as high as 35% (Lichtenstein et al, 2000). Although very
common in the general population, considering an additive model
of inheritance the 10 SNPs discovered so far (9p24 excluded)
account jointly for only about 6% of the excess genetic risk
(Houlston et al, 2008). These statements leave the majority of the
genetic contribution to CRC development still unexplained and
Table 1 (Continued)
Locus/SNP OR published Genotypes No cases (%) No controls (%) OR (95% CI) P-values
20p12.3 CC 694 (39) 693 (40) 1
rs961253 1.14 (het) CA 806 (46) 791 (46) 1.02 (0.88–1.18) 0.813
1.24 (hom) AA 265 (15) 237 (14) 1.12 (0.91–1.37) 0.290
Houlston et al, 2008 CA+AA 1.04 (0.91–1.19) 0.568
Allelic 1.05 (0.95–1.16) 0.344
Trend 1.05 0.349
Abbreviations: allelic¼allele frequency difference; trend¼Armitage’s trend test; com¼common odds ratio; hom¼homozygous; het¼heterozygous; all¼allelic. Minor allele
frequencies Swedish cohort cases/controls: 8q23.3 (0.11/0.09), 8q24.21 (0.49/0.45), 9p24 (0.37/0.38), 10p14 (0.30/0.34), 11q23.1 (0.27/0.26), 14q22.2 (0.44/0.44), 15q13.3
(0.22/0.20), 16q22.1 (0.27/0.27), 18q21.1 (0.47/0.49), 19q13.1 (0.08/0.09), 20p12.3 (0.38/0.37). The bold values indicate Po0.05.
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Figure 1 Polygenic model of 11 CRC-related SNPs. Distribution of risk
alleles among cases and controls: black, cases; grey, controls.
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some more high-penetrant predisposing genes are welcomed.
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rs10795668 10p14 Sporadic % (no.) Familial % (no.) Total number of cases
AA 7.5 (101) 10.8 (42)
AG 43.1 (581) 45.1 (175)
GG 49.4 (667) 44.1 (171)
P¼0.046 1737
Age
rs10411210 19q13.1 p60% (no.) 460% (no.) Total number of cases
TT 1.5 (6) 0.5 (7)
CT 12.7 (50) 15.7 (214)
CC 85.8 (339) 83.8 (1144)
P¼0.045 1760
Table 2 P-values from genotype–phenotype analysis of 11 CRC susceptibility loci
SNP/loci rs16892766 rs6983267 rs719725 rs10795668 rs3802842 rs4444235 rs4779584 rs9929218 rs4939827 rs10411210 rs961253
Phenotype 8q23.3 8q24.21 9p24 10p14 11q23.1 14q22.2 15q13.3 16q22.1 18q21.1 19q13.1 20p12.3
Age of onset P¼0.277 P¼0.0014 P¼0.414 P¼0.035 P¼0.683 P¼0.070 P¼0.782 P¼0.055 P¼0.606 P¼0.045 P¼0.853
Sex P¼0.251 P¼0.190 P¼0.547 P¼0.313 P¼0.892 P¼0.880 P¼0.688 P¼0.784 P¼0.569 P¼0.069 P¼0.561
Family history P¼0.998 P¼0.131 P¼0.474 P¼0.046 P¼0.607 P¼0.587 P¼0.861 P¼0.459 P¼0.131 P¼0.071 P¼0.489
Rectum/colon P¼1.000 P¼0.789 P¼0.705 P¼0.170 P¼0.787 P¼0.407 P¼0.229 P¼0.184 P¼0.472 P¼0.632 P¼0.159
Location left/right P¼0.469 P¼0.277 P¼0.240 P¼0.246 P¼0.962 P¼0.347 P¼0.309 P¼0.709 P¼0.314 P¼0.505 P¼0.985
Genotype–phenotype analysis. The bold values indicate Po0.05.
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